MoonLake Immunotherapeutics Reports Q1 2026 Results, Advances Sonelokimab Towards BLA Submission
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics reported higher Q1 losses but confirmed a Q3 2026 BLA submission target for its lead asset, sonelokimab, in HS following a positive FDA meeting, supported by recent ATM capital raises.
Key Events · Product Development and Regulatory · MLTX
-
Q1 2026 Financial Performance
Reported a net loss of $69.7 million for Q1 2026, an increase from $40.6 million in Q1 2025, driven by a 49.5% rise in Research and Development (R&D) expenses to $54.5 million for clinical trials and pre-launch inventory.
-
Cash Position and Runway
Maintained a cash and marketable securities balance of $357.9 million as of March 31, 2026, with management projecting sufficient capital to fund operations through the end of 2027.
-
ATM Capital Raise
Sold 336,559 Class A Ordinary Shares for $6.0 million in Q1 2026 and an additional 1,481,330 shares for $27.5 million in April 2026 under its existing At-The-Market (ATM) program, with $258.8 million remaining for future sales.
-
Sonelokimab Regulatory Progress
Announced positive outcomes from its final pre-BLA meeting with the FDA for sonelokimab in Hidradenitis Suppurativa (HS), confirming a Biologics License Application (BLA) submission target for Q3 2026 and a potential US commercial launch in H2 2027.
Analysis · MLTX · Life Sciences
MoonLake Immunotherapeutics reported increased net losses and cash burn in Q1 2026, which is typical for a clinical-stage biotechnology company. The company successfully raised $33.5 million through its existing At-The-Market (ATM) program in Q1 and April 2026, extending its cash runway to the end of 2027. Critically, the company announced positive progress from its final pre-BLA meeting with the FDA for sonelokimab in Hidradenitis Suppurativa (HS), confirming a Biologics License Application (BLA) submission target for Q3 2026 and a potential US commercial launch in H2 2027. This regulatory advancement is a significant de-risking event and a major value driver for the company. However, new 10b5-1 trading plans adopted by the CEO and CSO, alongside an ongoing class action lawsuit, introduce some negative sentiment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $18.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.